HF
KPTI icon

HRT Financial’s Karyopharm Therapeutics KPTI Stock Holding History

HRT Financial’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-9,836
Closed -$128K – 2802
2024
Q2 		$128K Buy
+9,836
New +$163K ﹤0.01% 1730
2023
Q3 		– Sell
-15,035
Closed -$403K – 2770
2023
Q2 		$403K Buy
+15,035
New +$648K ﹤0.01% 1463
2022
Q3 		– Sell
-3,269
Closed -$221K – 3185
2022
Q2 		$221K Buy
+3,269
New +$300K ﹤0.01% 2202
2022
Q1 		– Sell
-16,555
Closed -$1.6M – 3483
2021
Q4 		$1.6M Buy
+16,555
New +$1.65M 0.01% 786
2021
Q1 		– Sell
-1,066
Closed -$247K – 2926
2020
Q4 		$247K Buy
+1,066
New +$247K 0.01% 1405

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

HRT Financial's KPTI Position: Q3 2024 in Review

HRT Financial sold out of Karyopharm Therapeutics (KPTI) in Q3 2024, closing a stake of 9,836 shares — an estimated $128K sold.

HRT Financial first reported a position in KPTI in Q4 2020 and held it in 5 quarters. The position peaked at $1.6M in Q4 2021. 91 funds tracked by Wall St. Rank hold KPTI as of Q3 2024.

  • HRT Financial reported no remaining Karyopharm Therapeutics position as of Q3 2024 after selling out during the quarter.
  • HRT Financial sold 9,836 Karyopharm Therapeutics shares in Q3 2024, an estimated $128K.
  • HRT Financial first reported a position in Karyopharm Therapeutics in Q4 2020 and held it in 5 quarters.
  • HRT Financial's Karyopharm Therapeutics position peaked at $1.6M in Q4 2021.
  • 91 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2024.

Based on HRT Financial's 13F filing for Q3 2024, filed 12 Nov 2024.